Abstract
Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferior. We analyzed hematopoietic cell transplantation recipients with AML and MDS who received fludarabine with once-daily intravenous busulfan targeted to either area under the curve (AUC) 5300 µM*L/min (Flu/Bu 5300) (n = 246) or AUC 3500 µM*L/min (Flu/Bu 3500) (n = 81), or Flu/Mel (n = 69). Flu/Bu regimens were compared separately to Flu/Mel. After 2-year follow-up, no differences in overall or relapse-free survival were found between Flu/Bu 5300 or 3500 versus Flu/Mel though relapse rates were significantly higher; 33.1% (p = 0.024), 44.6% (p = 0.002), versus 19.4%, respectively. Flu/Bu 5300 (p = 0.008) and Flu/Bu 3500 (p < 0.001) groups were prognostic for relapse compared to Flu/Mel. Flu/Mel yields lower relapse rates and similar survival benefit when compared to Flu/Bu 3500 or 5300 µM*L/min.
References
Jul 5, 2005·Blood·Mohamed L SorrorBarry Storer
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Aug 11, 2007·Leukemia·A ShimoniA Nagler
Sep 9, 2008·Blood·Corey CutlerRobert Soiffer
Feb 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltBrenda Sandmaier
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea BacigalupoMary Horowitz
Jan 28, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Janelle PerkinsClaudio Anasetti
Apr 3, 2010·Hematology/oncology Clinics of North America·Matthias Bartenstein, H Joachim Deeg
Jun 2, 2010·Haematologica·Jacopo Peccatori, Fabio Ciceri
Oct 12, 2010·Journal of Hematology & Oncology·Joseph PidalaHugo F Fernandez
Jun 13, 2012·Haematologica·Joseph PidalaClaudio Anasetti
Jun 20, 2012·Blood·Philippe ArmandHaesook T Kim
Jun 29, 2012·Blood·Peter L GreenbergDetlef Haase
Jun 11, 2014·Blood·Boglarka Gyurkocza, Brenda M Sandmaier
Aug 3, 2014·Haematologica·Claire OudinDidier Blaise
Nov 27, 2014·Cancer·Frédéric BaronMohamad Mohty
May 11, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Moussab DamlajMrinal M Patnaik
Jul 5, 2016·Internal Medicine·Wataru YamamotoShin Fujisawa
Apr 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart L ScottMitchell E Horwitz
May 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolaus KrögerTheo de Witte
Sep 12, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Koji KawamuraYoshinobu Kanda
Aug 24, 2018·Blood Advances·Mary EapenH Joachim Deeg
Citations
Jun 2, 2020·Leukemia & Lymphoma·Jingmei HsuFrédéric Baron
Aug 18, 2021·Transplantation and Cellular Therapy·Betül OranWael Saber
Aug 31, 2021·Clinical Lymphoma, Myeloma & Leukemia·Arnaud CampidelliMaud D'Aveni